Cargando…
Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators
INTRODUCTION: Vasodilator stress cardiovascular magnetic resonance (CMR) is a powerful diagnostic modality, but data toward its use in patients with permanent pacemakers (PPMs) or implantable cardioverter‐defibrillators (ICDs) is limited. METHODS AND RESULTS: Patients with ICDs (>1% pacing) or PP...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561044/ https://www.ncbi.nlm.nih.gov/pubmed/35842792 http://dx.doi.org/10.1111/jce.15630 |
_version_ | 1784807869720297472 |
---|---|
author | Miller, Lauren Airapetov, Sergei Pillai, Ajay Kalahasty, Gautham Ellenbogen, Kenneth A. Gregory Hundley, W. Trankle, Cory R. |
author_facet | Miller, Lauren Airapetov, Sergei Pillai, Ajay Kalahasty, Gautham Ellenbogen, Kenneth A. Gregory Hundley, W. Trankle, Cory R. |
author_sort | Miller, Lauren |
collection | PubMed |
description | INTRODUCTION: Vasodilator stress cardiovascular magnetic resonance (CMR) is a powerful diagnostic modality, but data toward its use in patients with permanent pacemakers (PPMs) or implantable cardioverter‐defibrillators (ICDs) is limited. METHODS AND RESULTS: Patients with ICDs (>1% pacing) or PPMs who underwent regadenoson single photon emission computed tomography (SPECT) and all patients with ICDs or PPMs who underwent stress CMR were retrospectively identified. SPECT tests were analyzed for hemodynamic responses and new pacing requirements; CMR studies were examined for safety, device characteristics and programming, hemodynamic responses, and image quality. Changes from baseline were evaluated with the Related‐Samples Wilcoxon Signed Rank Test. Of 67 patients (median age 65 [IQR 58–72] years, 31 [46%] female, 31 [46%] Black), 47 underwent SPECT and 20 CMR. With regadenoson SPECT, 89% of patients experienced tachycardic responses above resting heart rates (+19 [13–32] beats per minute, p < .01). During stress CMR, 10 (50%) devices were asynchronously paced approximately 10 beats per minute above resting rates, and the remaining were temporarily deactivated. Those with asynchronous pacing had no changes in heart rates, whereas patients with deactivated devices had near uniform heart rate accelerations. Image quality was diagnostic in the majority of stress CMR sequences, with nonconditional ICDs contributing 40 of 57 (70%) of nondiagnostic segments. CONCLUSION: This data supports the safety of vasodilator stress CMR with promising diagnostic quality images in patients with CMR conditional ICDs and PPMs. Despite a near uniform tachycardic response to regadenoson in the SPECT environment, high rates of asynchronous pacing during vasodilator stress CMR did not result in competitive pacing or adverse arrhythmic events. Further studies are needed to validate these findings and confirm the diagnostic and prognostic performance of stress CMR in these individuals. |
format | Online Article Text |
id | pubmed-9561044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95610442022-12-30 Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators Miller, Lauren Airapetov, Sergei Pillai, Ajay Kalahasty, Gautham Ellenbogen, Kenneth A. Gregory Hundley, W. Trankle, Cory R. J Cardiovasc Electrophysiol Featured Articles INTRODUCTION: Vasodilator stress cardiovascular magnetic resonance (CMR) is a powerful diagnostic modality, but data toward its use in patients with permanent pacemakers (PPMs) or implantable cardioverter‐defibrillators (ICDs) is limited. METHODS AND RESULTS: Patients with ICDs (>1% pacing) or PPMs who underwent regadenoson single photon emission computed tomography (SPECT) and all patients with ICDs or PPMs who underwent stress CMR were retrospectively identified. SPECT tests were analyzed for hemodynamic responses and new pacing requirements; CMR studies were examined for safety, device characteristics and programming, hemodynamic responses, and image quality. Changes from baseline were evaluated with the Related‐Samples Wilcoxon Signed Rank Test. Of 67 patients (median age 65 [IQR 58–72] years, 31 [46%] female, 31 [46%] Black), 47 underwent SPECT and 20 CMR. With regadenoson SPECT, 89% of patients experienced tachycardic responses above resting heart rates (+19 [13–32] beats per minute, p < .01). During stress CMR, 10 (50%) devices were asynchronously paced approximately 10 beats per minute above resting rates, and the remaining were temporarily deactivated. Those with asynchronous pacing had no changes in heart rates, whereas patients with deactivated devices had near uniform heart rate accelerations. Image quality was diagnostic in the majority of stress CMR sequences, with nonconditional ICDs contributing 40 of 57 (70%) of nondiagnostic segments. CONCLUSION: This data supports the safety of vasodilator stress CMR with promising diagnostic quality images in patients with CMR conditional ICDs and PPMs. Despite a near uniform tachycardic response to regadenoson in the SPECT environment, high rates of asynchronous pacing during vasodilator stress CMR did not result in competitive pacing or adverse arrhythmic events. Further studies are needed to validate these findings and confirm the diagnostic and prognostic performance of stress CMR in these individuals. John Wiley and Sons Inc. 2022-07-28 2022-10 /pmc/articles/PMC9561044/ /pubmed/35842792 http://dx.doi.org/10.1111/jce.15630 Text en © 2022 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Featured Articles Miller, Lauren Airapetov, Sergei Pillai, Ajay Kalahasty, Gautham Ellenbogen, Kenneth A. Gregory Hundley, W. Trankle, Cory R. Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title | Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title_full | Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title_fullStr | Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title_full_unstemmed | Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title_short | Hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
title_sort | hemodynamic response and safety of vasodilator stress cardiovascular magnetic resonance in patients with permanent pacemakers or implantable cardioverter‐defibrillators |
topic | Featured Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561044/ https://www.ncbi.nlm.nih.gov/pubmed/35842792 http://dx.doi.org/10.1111/jce.15630 |
work_keys_str_mv | AT millerlauren hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT airapetovsergei hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT pillaiajay hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT kalahastygautham hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT ellenbogenkennetha hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT gregoryhundleyw hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators AT tranklecoryr hemodynamicresponseandsafetyofvasodilatorstresscardiovascularmagneticresonanceinpatientswithpermanentpacemakersorimplantablecardioverterdefibrillators |